Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577467 · ClinicalTrials.gov registry record
Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection
A clinical trial of PASC Post Acute Sequelae of COVID 19, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Recruiting
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT06577467: Recruiting study of PASC Post Acute Sequelae of COVID 19, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT06577467 is a study of PASC Post Acute Sequelae of COVID 19 that is actively recruiting participants, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 12 participants, below the 230-participant average among 6 other PASC Post Acute Sequelae of COVID 19 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577467, a study of PASC Post Acute Sequelae of COVID 19, is actively recruiting participants, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends. This is called long COVID. Sometimes, long COVID can affect the nerves and cause problems with sleep, thinking, the senses, and movement. Researchers want to find out whether people with long COVID have retained inactive remnants of SARS-CoV-2 in their bodies. Objective: To collect tissue samples to see if people with long COVID have remnants of SARS-CoV-2 in their bodies. Eligibility: People 18 years or older who have recovered from COVID-19, both with and without neurologic symptoms. Design: Participants will have 2 to 4 inpatient or outpatient visits over 4 months. Each visit will last 4 to 5 days. Participants will be screened to make sure it is safe to collect tissue samples from their body. They will have a physical and dental exam. They will have imaging scans and a test of their heart function. They will complete questionnaires about their health. They will give blood, urine, saliva, and stool samples. Their sense of taste and smell will be tested. Tissue samples will be taken from the digestive tract, lungs, colon, skin, muscle, lymph nodes, nasal passages, and mouth. Participants may be numbed or sedated for some of the procedures. Swabs will be used to collect cells from inside the mouth and nose. Participants will undergo lumbar puncture. A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord. Participants will have follow-up phone calls after each clinic visit.
Primary Outcome
This is an exploratory study to determine where SARS-CoV-2 viral remnants can be recovered in tissues of patients with Neuro-PASC.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2027-09-01 |
What NCT06577467 shows while recruiting
NCT06577467 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 230-participant average among 6 other PASC Post Acute Sequelae of COVID 19 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with PASC Post Acute Sequelae of COVID 19 appearing as the primary indexed condition, and to 0 interventions.
NCT06577467 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06577467 about?
NCT06577467 is a clinical study titled "Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection". Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends. This is called long COVID. Sometimes, long COVID can affect the nerves and cause problems with sleep, thinking, the senses, and movement. Res...
What is the current status of trial NCT06577467?
This trial is currently recruiting. The enrollment target is 12 participants. The study started on 2025-03-27. Estimated completion is 2027-09-01.
What conditions does trial NCT06577467 study?
This clinical trial studies the following conditions: PASC Post Acute Sequelae of COVID 19.
Who is sponsoring clinical trial NCT06577467?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577467 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PASC Post Acute Sequelae of COVID 19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2
RECRUITING · NA
-
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
RECRUITING · Early Phase 1
-
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
ACTIVE NOT RECRUITING
-
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
ACTIVE NOT RECRUITING · NA
-
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI